Cytokineticsorporated - 48 Year Dividend History | CYTK

Historical dividend payout and yield for Cytokineticsorporated (CYTK) since 1971. The current TTM dividend payout for Cytokineticsorporated (CYTK) as of April 24, 2019 is $0.00. The current dividend yield for Cytokineticsorporated as of April 24, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.516B $0.032B
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $109.824B 12.37
Gilead Sciences (GILD) United States $80.063B 10.19
Bio-Techne Corp (TECH) United States $7.211B 48.58